Showing posts with label k k aggarwal. Show all posts
Showing posts with label k k aggarwal. Show all posts

Wednesday, July 15, 2020

154 CMAAO CORONA FACTS and MYTH Round the globe


154 CMAAO CORONA FACTS and MYTH Round the globe

Dr K Aggarwal
President CMAAO
With inputs from Dr Monica Vasudev


976: Good news: So far, no documented outbreak of COVID-19 in the U.S. has been traced to a dental office notes the American Dental Association.

977: July 6 by Annals of Internal Medicine: For the SARS-CoV-2 IgG assay, sensitivity and specificity were 0.976 and 0.988  respectively, when the test was performed at least 14 days after symptom onset. For tests done earlier, however, sensitivity was lower. IgG levels remained high during follow-up, up to 58 days. Levels of antibodies to SARS-CoV-2 were related to the risk for acute respiratory distress syndrome, with an increase of 62% for every twofold increase in IgG. Among the 11,066 patients who received a NAAT, 457 had repeatedly negative results. In serum samples obtained from 18 of these patients, six who were COVID-19 case-patients and 12 who were non-COVID-19 controls, five of six in the former group and none of 12 in the latter group had antibodies detected (P=0.001). The authors concluded that antibodies to SARS-CoV-2 can indicate infection when measured 14 or more days after symptom onset, are associated with clinical severity, and can provide diagnostic support when patients have negative results on NAAT but COVID-19 is still suspected.

978: An inexpensive two-drug regimen of sofosbuvir plus daclatasvir taken for 14 days significantly reduced time to recovery from COVID-19 and improved survival in people hospitalized with sever e disease, research from an open-label Iranian study led by Andrew Hill, PhD, from the University of Liverpool, United Kingdom shows.

979: A recent study of two hospitals in Wuhan, China, found that the highest aerosol concentration was in a bathroom, although it noted that it was a temporary, single-toilet room with no ventilation. The study also found that sanitization and ventilation effectively limited the virus’s concentration in aerosols. Another recent study that analyzed samples from patients hospitalized with COVID-19 found that attempts to isolate the virus from stool samples were never successful, and that existing fragments were not infectious.
The flush is a one-time event, and any direct plume is from a person’s own feces; if the virus was present, that person would already be infected. Our own fecal plume poses no risk to us,

980: If an unmasked interaction within six feet lasts under 15 minutes and doesn’t include coughing or sneezing, the transmission risk is still low.

981: Music might be playing, causing people to lean in and speak to each other.

982: Alcohol can make people relax and forget about distancing, and when there’s singing, breaths are forcibly ejected into the air. In many of these settings, masks might not be required and might not be worn, further encouraging the spread.

983: And before you leave, use your foot, elbow (if possible), or a paper towel to open the door, and once outside, spray your hands with a sanitizer.

984:  -- Bodies stressed by severe COVID-19 could produce abnormally high blood sugar levels, even in people without diagnosed diabetes. And that appears tied to a doubling of the odds of dying from COVID-19, Chinese researchers report. High blood sugar (glucose) levels, measured at the time of admission to the hospital, were also linked to more severe disease and complications, according to researchers led by Dr. Yang Jin, of the Union Hospital and Tongji Medical College, in Wuhan, China. Wuhan was the originating epicenter of the global pandemic of COVID-19. [ July 10 in the journal Diabetologia.

985:  Even if the virus were to land on food that you ate, there’s no evidence that swallowing the virus leads to infection. It needs to be transmitted to the respiratory system – into the nose, sinuses or lungs.





Tuesday, July 14, 2020

153 CMAAO CORONA FACTS and MYTH BUSTER ICMR Vaccine


153 CMAAO CORONA FACTS and MYTH BUSTER  ICMR Vaccine

Dr K Aggarwal
President CMAAO
With inputs from Dr Monica Vasudev
975: Round Table Expert Zoom Meeting on “Covid-19 vaccine update

17th July, 2020, 11am-12pm

Participants

Dr KK Aggarwal
Dr Ashok Gupta
Dr AK Agarwal
Dr Ashok Gupta
Dr Suneela Garg
Dr DR Rai
Dr Narottam Puri
Dr JA Jayalal
Dr Jayakrishnan AV
Dr Alex Thomas
Dr Atul M Kochhar
Dr Glory Alexander
Ms Meenakshi Datta Ghosh
Mrs Upasana Arora
Dr K Kalra
Ms Ira Gupta
Dr S Sharma

Faculty

Dr NK Ganguly
Former Director-General, ICMR

Key points from the discussion

  • A herd immunity of 60-70% is required to stop the spread of infection in the community; however, development of herd immunity will take time. This can be achieved with vaccine.
  • A vaccine which gives 40% protection may not be ideal; if it gives 70% protection, it will stop transmission.
  • In India, phase 1 and 2 trials only; phase 3 yet to be done. Nineteen of the vaccines around the world have completed phase 1 or are in/completed phase 2 and have entered phase 3. Some international vaccines have entered phase 3, so may come out with a vaccine earlier than us.
  • US FDA has brought out separate guidelines for animal toxicology studies for Covid vaccine.
  • Different platforms are being used to make the vaccine safe. Very limited amount of the viral protein (such as preformed spike protein, receptor binding domain [RBD]) is used to make it as safe as possible. The whole cell vaccine (killed or attenuated) may cause problems as they contain all viral antigens, which might produce immune responses.
  • Immune responses in humans differ. This is why three age groups will receive the vaccine: 18-55, 55-70, ≥70. Different concentrations are taken and multiple injections are needed – one to prime and the second to boost.
  • Will the vaccine work will depend on whether neutralizing antibodies are formed. They are checked in two formats: live virus and ghost cells. Moderna vaccine (synthetic vaccine) was able to get neutralizing antibodies in 8 of its subjects and it also passed safety (there will be some swelling, redness at the site, fever, nausea but no serious adverse effects like cytokine storm, autoimmune reaction). Moderna has finished phase 2, but they have not published.
  • Pfizer has taken four different constructs of mRNA vaccine with BioNTech. Two of them have completed phase 2.
  • In India, Gennova Pharmaceuticals is developing mRNA vaccine and have almost finished preclinical studies. Their results in mice are good and in monkey challenge are excellent. They have completed studies on plasma and did not find any autoimmune reaction, cytokine storm or any deleterious immune reaction.
  • Till phase 3 is done, there is no certainty that the vaccine will succeed. People may react differently according to the endemicity like the Rota virus vaccine.
  • No mRNA vaccine is in the market yet. Moderna and Pfizer vaccines have gone into human trials; Gennova are almost completing the animal and preclinical studies.
  • Spike protein vaccine (Astrazeneca and Oxford vaccine). They have given license to several companies. In India, license has been given to Serum Institute of India. If the vaccine succeeds in phase 2, they will start manufacturing and release the vaccine as an emergency vaccine if phase 3 is successful.
  • Novavax vaccine: Phase 2 is completed.  It is entering phase 3 trials in Australia and Brazil. Matrigel adjuvant is used. It is funded by BARDA. Novavax has a joint venture with Cadila Pharma called CLP Biologicals in Ahmedabad.
  • There is a global list of 19 prospective companies; no Indian company features on this list.
  • The Johnson & Johnson vaccine is using Adeno-26 platform and pre-fusion spike protein, which has been successfully used by them in Ebola vaccine (RNA vaccine) and RSV vaccine. J&J has so far no agreement with any Indian company, but they are talking to Aurobindo, which has bought a small vaccine company from Pfizer in the US. It is using a vesicular stomatitis virus platform for vaccine development, which is likely to be manufactured in their unit in Hyderabad.
  • Bharat Biotech vaccine:  It is a whole cell killed vaccine. There are few challenges: If it has an alum adjuvant, then it might produce immune response. Since there are no human trials yet, we do not know how it will behave.
  • Sinovac inactivated whole virus vaccine from China might be the first vaccine available. It is alum adjuvanted and is already in human trials. Formaldehyde is used to inactivate the virus.
  • Most vaccine products are being tested in multiple countries.
  • In India, the regulatory pathway to monkey studies is very long. For animal studies (monkey), one may have to go outside India (Gennova). There are very few BSL 3 facilities to do animal challenge studies.
  • Many convalescent plasma have very little neutralizing antibodies. Some of them have almost no antibodies. The amount is not the same as it is produced in other infections.
  • The amount of antibodies and the quality of antibodies which the vaccine will produce will be very critical.
  • NK cells are markers of innate immunity. If NK cells are okay, then it is better.
  • Mutations in the virus are happening rapidly now.
  • Monoclonal therapy: One single antibody may not work so a cocktail of three antibodies is preferred. Tocilizumab is actually IL-6 inhibitor.
  • Safety of the vaccine was a cause for concern because of the nature of the virus right from Day 0. It attacks all organs through immunological response (cytokine storm). This is why manufacturers are trying to take as little as possible of the virus. Age difference is critical; hence, three groups of populations are being studied in trials. Like influenza vaccine, this vaccine may need to be taken every year.
  • Cost of the vaccine will be a challenge.

























































 



Monday, July 13, 2020

152 CMAAO CORONA FACTS and MYTH BUSTER Covid in Children, Neurology


152 CMAAO CORONA FACTS and MYTH BUSTER Covid in Children, Neurology

Dr K Aggarwal
President CMAAO
With inputs from Dr Monica Vasudev
9743: Minutes of Virtual Meeting of CMAAO NMAs on “Covid in children & Covid and neurology”

11th July, 2020, Saturday, 9.30am-10.30am

Participants, Member NMAs

Dr KK Aggarwal, President CMAAO
Dr Yeh Woei Chong, Singapore Chair CMAAO
Prof Ashraf Nizami, Pakistan First Vice President CMAAO
Dr N Gnanabaskaran, President Malaysian Medical Association
Dr Marthanda Pillai, Member World Medical Council
Dr Alvin Yee-Shing Chan, Hong Kong, Treasurer CMAAO
Dr Koh Kar Chai, Malaysia Co Chair CMAAO
Dr Marie Uzawa Urabe, Japan Medical Association
Dr Qaisar Sajjad, Pakistan Medical Association, Secretary
Dr Prakash Budhathoky, Nepal Medical Association

Invitees

Dr Russell D’Souza, UNESCO Chair in Bioethics, Australia
Dr Sanchita Sharma, Editor IJCP Group


Prof Ashraf Nizami and Dr Alvin Yee-Shing Chan spoke on Covid in children and Covid and neurology, respectively. Here are key points from each presentation.

Covid-19 in children and Pakistan

Prof Ashraf Nizami
First Vice President CMAAO
Immediate Past President PMA Center
President PMA Lahore

In his presentation, Prof Ashraf Nizami spoke on Covid-19 in children and also highlighted the role of government and particularly the Pakistan Medical Association (PMA) in dealing with Covid-19 in Pakistan. The first case was reported in Pakistan on 6th February.

  • There was a general perception that children are not affected by this pandemic. But the fact is that all children of all ages in all countries are affected. This is a universal crisis and will have lifelong impact for some children as it is not just a health issue. It is also social and psychological issue.

  • Clinical symptoms in children include abdominal pain, diarrhea and vomiting, red rash, cracked lips, red eyes, high fever, swollen glands on neck and swollen hands and feet.

  • As per data on July 1, about 7.28% of the total reported cases in Pakistan are in people below 19 years of age. The mortality is 0.46% (16 out of 3501 under 15 years). Three suspected cases of Kawasaki disease have been reported in Lahore; also from Karachi, Rawalpindi and Islamabad.

  • Covid has an impact on social growth. About 30% of industry is affected. Education is disturbed and only about 30% of children in Pakistan have access to technology in education (online). Healthcare services have been affected. Covid has also affected the physical and mental growth of children.

  • The pandemic has led to anxiety and depression not only in children but also the parents. Incidence of domestic violence against women has increased due to lockdown, which has an impact on children and the family. Exploitation and child abuse have happened.

  • Covid-19 has compromised access to health services due to lockdown; the basic health services are delayed due to SOPs in place. Polio vaccination has been affected; besides Pakistan and Afghanistan, recent outbreaks have been reported in Africa, East Asia and the Pacific.

  • The government is creating awareness about the disease; special institution have been designated for children. Special counters have been created in hospitals.

  • According to UNICEF, adequate water, sanitation and hygiene services for households, schools and healthcare facilities are essential to prevent spread of infectious diseases including Covid-19; 3 billion homes do not have soap and water; 900 million children do not have soap and water at schools.

  • PMA is an active participant in Covid-19 activities. It was the first organization in Pakistan which spoke about Covid-19 and created awareness and raised an alarm about the outbreak. It also looks after coordination among doctors, government, social activities and people. A scientific meeting was organized for family physicians, who are considered as front liners. PMA is also developing guidelines with information derived from WHO, CMAAO, London School of Economics etc.

  • PMA is working on telemedicine facilities, analysis of government policies, plans and actions. It is playing an active role in advocacy and implementation of WHO recommendations as per local needs as well as international experiences.

  • PMA is pressing upon the government that curative services should not be compromised, to start immunization services with all SOPs; it is critical of the government’s decision to reopen schools. Psychology and psychiatric teleconsultations are being planned.


Covid and Neurology

Dr Alvin Yee-Shing Chan
Treasurer CMAAO
Vice Chairman, HKMA Charitable Foundation

  • About 36.4 % of Covid patients from Wuhan China had neurological involvement; manifestations were more in cases of severe infection.

  • Acute cerebrovascular diseases occurred in 5.7% of those severe cases vs 0.08% of milder cases.

  • 14% of severe cases had impaired consciousness vs 2.4% of mild cases.

  • Musculoskeletal injury occurred in 19.3% of severe cases vs 4.8% of mild cases.

  • Neurological signs and symptoms are much higher in patients in intensive care: mental confusion and agitation (69%), diffuse corticospinal tract signs with enhanced tendon reflexes, ankle clonus, bilateral extensor plantar reflexes (67%).

  • 33% of discharged patients (33%) had dysexecutive syndrome consisting of inattention, disorientation, or poorly organized movements in response to command

  • MRI brain, in most of the patients, will show leptomeningeal enhancement, bilateral frontotemporal hypoperfusion, ischemic stroke; encephalopathic pattern on EEG.

  • Clinically, these patients may have milder symptoms (hyperosmia, anosmia, headache, weakness, altered consciousness); patients with more severe infection have encephalitis with demyelination, neuropathy, and stroke.

  • Invasion of the medullary cardiorespiratory center by the SARS CoV-2 virus may cause refractory respiratory failure in ICU patients.

  • The route of entry is mostly through olfactory bulbs – olfactory tracts in the brain.

  • Human coronaviruses have neuroinvasive capability. Misdirected host immune responses can damage the CNS, which is associated with autoimmunity in the susceptible persons, resulting in virus induced neuro-immunopathology. The virus replication directly damages the CNS.  ACE2 receptors occur in olfactory epithelium 70 times more than in tracheal or nasal epithelium. This is why anosmia occurs so frequently in this disease.

  • The ACE2 receptor expression differs in neurons and glial cells and so immunopathology differs in different persons.

  • Since ACE2 receptors are present in brain cells, the BBB presents no problem to the new corona virus. The virus has been detected in brain samples on autopsies and offers an explanation about the neurological sequelae even when the patients survive.

  • Possible mechanism of direct neuronal damage: The trans-neuronal retrograde machinery is a possible route of neuronal invasion. The virus first infects peripheral neurons to invade the CNS via the axonal retrograde transport. It infects another neuron via synapses. The virus is released by exocytosis in the presynaptic terminal. It then binds to ACE2 receptor on the postsynaptic neuron. It gains entry into the neuroplasm via the receptor-mediated endocytosis. It causes cell death via apoptosis.

  • Covid-19 induces anti-cardiolipin antibodies endothelialitis thrombosis (venous and arterial) stroke, cerebrovascular accidents.

  • The direct attack on neurons will cause milder cases, but if there is massive invasion of key neuronal cells, this may cause dysexecutive function. The vasculitis and endothelitis is instrumental in severe cases stroke, and cell death due to ischemia.

  • Hong Kong has very few pediatric patients and they have mild infection. There is resurgence in community spread with more than 40 cases with no obvious source. 7500 tests in a day, which is inadequate. No medical health staff has been infected through hospital or clinic. The silent cases in community are a cause of concern.

Acute presentation

Dr KK Aggarwal
President CMAAO

Look for the following points in every patient who presents with onset of illness less than
3 months. Classifying patients accordingly makes it easier to manage them.

  • Is the clinical presentation of Covid is due to inflammation? There will be signs of inflammation like IL-6, ESR, CRP, ferritin Give anti-inflammatory drugs; steroids are the most potent anti-inflammatory drugs
  • Can this be because of hypercoagulable state? e.g. thrombotic stroke/MI/appendicitis/gangrene/happy hypoxia (microclot formation in lung vessels): Do d-dimer; high d-dimers mean hypercoagulable state  
  • Is there any immunological reaction (immediate or delayed) - humoral? Vasculitis, look for rash, CRP is normal, high platelets;
  • Is there cellular immunological response? Cytokine crisis
  • Except for hypercoagulable state, all will respond to steroids. So, combination of LMWH and steroids is standard treatment.
  • Some patients may have simple viral response and illness will resolve spontaneously in 2-3 days; some will show a bacterial response with slightly high polymorphs – typhoid test may be falsely positive in such patients; some patients may have low CD4 count indicating HIV-like activity.



























































































 


Sunday, July 12, 2020

151 CMAAO CORONA FACTS and MYTH BUSTER LAB TESTING


151 CMAAO CORONA FACTS and MYTH BUSTER LAB TESTING

Dr K Aggarwal
President CMAAO
With inputs from Dr Monica Vasudev

973: IMA-CMAAO Webinar on “Covid testing” 11th June, 2020 4-5pm

Participants
Dr KK Aggarwal, President CMAAO
Dr RV Asokan, Hony Secretary General IMA
Dr Ramesh K Datta, Hony Finance Secretary IMA
Dr Jayakrishnan Alapet
Dr Brijendra Prakash
Dr Girdhari Kanuga
Dr Sanchita Sharma

Faculty

Dr Shalabh Malik
National Head Microbiology
Dr Lal Path Labs

Key points from the discussion

  • The coronavirus is a new virus and with no proven therapy or a vaccine as of date, diagnostic testing becomes an important tool for management of patient with Covid-19.

  • Lab test options available: Molecular, antigen (point of care test, CARD test) and antibody (rapid – not allowed in India so far, CLIA – automated platform, ELISA, IgG/IgM, total (combination of IgG and IgM)

  • Molecular: Conventional (results within 6-8 hours), Automated, which is a closed system – CB-NAAT (gives result in 45 minutes), TruNat (within 2 hours; it first screens for envelope (E) gene, which is common to all coronaviruses and then RdRP [RNA-dependent RNA polymerase] gene, which is specific for Covid-19).

  • The purpose of testing is diagnostic, sero-surveillance, or to know exposure (as around 40-45% of cases are asymptomatic) or immunity levels.

  • Covid testing in India is very regulated, as per ICMR and government guidelines. RT PCR is gold standard investigation; recently Antigen test has been allowed.

  • As per ICMR revised guidelines, patients to be selected for testing include symptomatic international traveler in last 14 days, symptomatic contact of lab confirmed case, symptomatic healthcare worker, hospitalized SARI patient, asymptomatic direct and high risk contact of lab-confirmed cases, asymptomatic healthcare worker in contact with confirmed case without adequate precaution and symptomatic ILI patient in hospital/clusters as identified by the Health ministry.

  • Pre-requisites before testing: As it is a pandemic, every result has to be notified. Doctor’s prescription + Covid-19 ICMR form (patient details, history, clinical features, Govt. ID) is mandatory requirement; infrastructure (BSL-3 or at least BSL-2 facility), trained personnel, waste disposal, judicious training and use of PPE are other testing pre-requisites.

  • Specimen type: nasopharyngeal/oropharyngeal swab; nasopharyngeal has better sensitivity – proper sample collection is crucial. Nylon swabs are used as coronavirus stays longer on synthetic material. Then immediately transfer to VTM (viral transport medium); shipped at 2-8oC with appropriate 3-layer packing. In later stages of infection, bronchoalveolar lavage or endotracheal aspirate is better. Recent studies have shown saliva to be better than nasopharyngeal or oropharyngeal swab.

  • RT PCR: Minimum two gene targets (E gene and RdRP gene) need to be pinpointed to declare as RT PCR positive. More the number of targets better is the sensitivity.

  • If E gene, Rd RP gene and RP gene are positive, this confirms detection of SARS-CoV-2. If one gene is positive and the other is negative, the test is inconclusive; repeat the test or take a fresh sample. If E gene and Rd Rp gene are negative and R P gene is positive, the test is negative for SARS CoV-2 virus.

  • It is a qualitative test as it does not give quantitative assay of viral load. Ct (cycle threshold) can give a clue about the severity of infection. If Ct value is low, this indicates high viral load. If high Ct value, this indicates low viral load. Every lab should report Ct value.

  • All reporting (negative/positive) is done on ICMR website and is highly confidential.

  • Advantages of RT PCR: Speed and sensitivity, early detection and isolation, identification of infected persons which helps in management and implementation of mitigation strategies in containment areas

  • Disadvantages of RT PCR: BSL3 or 2 level facilities are required, PPE training, skilled personnel, false negative test (sampling error, very early disease, incorrect transportation)

  • Rapid antigen test: ICMR recommended (14.6.20), sample collection to reading the result should be done within one hour, prescription/Form 44 are mandatory. If antigen test is negative, but person has symptoms suggestive of Covid-19, then RT PCR is mandatory. Sensitivity is around 50-53%. Specificity is good.

  • Antibody tests: Not used for diagnosis, only for seroprevalence studies; community screening of asymptomatic infections, contact tracing, evaluate results of vaccine trials, immunity. Notification is a must; prescription and form are not mandatory.

  • IgM appears first and then IgG. IgM appears around Day 4, rises to peak around Day 14 and disappears by Day 28. IgG appears around Day 8/9, rises to peak around Day 21 and then stays on. The longevity of IgG is not known. So retesting is done after 3 months.

  • Three types of seroconversion are seen in Covid-19: IgG and IgM may appear at the same time (synchronous seroconversion), IgM seroconversion earlier than IgG, IgM seroconversion later than IgG.

  • There is no advisory yet on IgM testing.

  • Total antibody (IgG + IgM) positive: Exposure to SARS CoV-2 is confirmed and antibodies have developed. If symptomatic, refer to RTPCR; if asymptomatic, then quarantine and repeat IgG x7-10 days.

  • Total antibody (IgG + IgM) negative: Exposure not confirmed, antibodies not developed. If person is symptomatic, do RT PCR; if asymptomatic, then this confirms negative result.

  • Surgical or medical intervention emergency: If antigen negative, antibody positive – is symptomatic, then do PCR; if asymptomatic, then go ahead with surgery.

  • Back to work: If IgG positive, join work (retest after 3 months), if IgG negative and symptomatic, do RT PCR (If positive, quarantine; if negative retest IgG after 14 days), if IgG negative and asymptomatic, join work.

  • Cross reactivity with other viruses like dengue or bacteria like typhoid is being seen.

  • Best test when deciding plasma donor is neutralization test. This requires BSL3+ facility.

  • If PCR positive, antigen negative: low viral load. For antigen test to be positive, high viral load is required. PCR is sensitive for low viral load.




























Summary of testing for Covid 19

Test
Ideal time to test from onset of illness
Use
Advantages
Limitations
RT PCR
0-14 days
Confirmatory test
High sensitivity
Best for testing symptomatic persons
High cost of infrastructure

Complex sample collection and handling

High TAT 2.5-3 hours for testing 1 patient

Rapid Antigen
0-14 days
Acute and early infection
Faster result
Cost effective
Can be used for mass screening
Relatively low sensitivity vs RT PCR

Complex sample collection and handling

SARS CoV-2 IgM
4-21 days
Community screening for detecting active and early infections

Shorter turnaround time
Easy sample collection and transport
Cost effective
High throughput analyzers present across the country
Limited evidence on clinical efficacy of serology based Antibody tests

Can’t be used for detecting early infections esp 0-4 days
SARS CoV-2 IgG
≥ 7 days
Assess immunity
Screen potential plasma donors
Assess recovery and past exposure to the virus, return to work










Saturday, July 11, 2020

150 CMAAO CORONA FACTS and MYTH BUSTER AIR borne and WHO TOVILIZUMAB

150 CMAAO CORONA FACTS and MYTH BUSTER AIR borne and WHO TOVILIZUMAB

Dr K Aggarwal
President CMAAO
With inputs from Dr Monica Vasudev

971:  New WHO Guidance Calls for More Evidence on Airborne Transmission

1.    The WHO on Thursday released new guidelines on the transmission of the novel coronavirus that acknowledge some reports of airborne transmission of the virus that causes COVID-19, ut stopped short of confirming that the virus spreads through the air.
2.    WHO acknowledged that some outbreak reports related to indoor crowded spaces have suggested the possibility of aerosol transmission, such as during choir practice, in restaurants or in fitness classes. (https://bit.ly/2Ck7QBo)
3.    WHO said the coronavirus that causes COVID-19 spreads through contact with contaminated surfaces or close contact with infected people who spread the virus through saliva, respiratory secretions or droplets released when an infected person coughs, sneezes, speaks or sings.
4.    People should avoid crowds and ensure good ventilation in buildings, in addition to social distancing, and encourage masks when physical distancing is not possible.
5.    Pandemic is driven by super-spreading events, and that the best explanation for many of those events is aerosol transmission
6.     People without symptoms - to wear masks.
7.    Only a very small number of diseases are believed to be spread via aerosols, or tiny floating particles. These include measles and tuberculosis - two highly contagious pathogens that can linger in the air for hours and require extreme precautions to prevent exposure.
8.     WHO is using an "outdated definition of droplets and aerosols" and is too focused on the size of the droplets and the distance they travel. WHO defines aerosols as being under 5 microns because only particles that small could float in the air long enough to be inhaled. However, Linsey Marr, an aerosol expert at Virginia Tech  said a much larger range of particle size has been shown to contribute to infection. Rather than size, the differences between droplets and aerosols should be based on how the infection occurs: If a person inhales the virus and becomes infected, it's an aerosol. If the infection occurs by contact, they are droplets. Although WHO has been focused on airborne transmission at long distances, Marr said breathing in aerosols "is of greater concern at close contact and when people are in the same room. [Reuters]

972: Predictors of survival in COVID-19 patients treated with tocilizumab

1.     Receipt of the IL-6 receptor antagonist tocilizumab within 12 days of symptom onset in patients with severe coronavirus disease 2019 (COVID-19) was an independent predictor for in-hospital survival at 28 days, according to a study published in the Journal of Autoimmunity.
2.      Patients were eligible for tocilizumab if they exhibited persistent fevers (38.0 °C for greater than 6 hours), had PaO2/FiOof < 200, and exhibited persistently rising inflammatory laboratory parameters (ferritin, D-dimer, and lactate dehydrogenase [LDH]) or an elevated inflammatory laboratory parameter defined as ferritin ≥1000 μg/L, D-dimer ≥ 5 mg/mL, or LDH ≥ 500 U/L. An IL-6 level ≥ five times the upper limits of normal (≤5 pg/ml) was assessed in addition to these parameters.
3.      Tocilizumab was administered as an 8 mg/kg IV dose using actual body weight with a maximum dose of 800 mg. Patients were eligible for a second dose if persistently febrile despite treatment. Due to medication shortages the tocilizumab dose was changed to a fixed 400 mg IV dose for all patients on March 30, 2020. All patients were followed for up to 28 days from the first dose.
4.      Results showed that the 28-day in-hospital mortality was 43.2%, leaving 46 patients in the survivors and 35 in the non-survivors group. According to the authors, the single independent predictor of 28-day in-hospital survival was receipt of tocilizumab within 12 days of symptom onset (adjusted OR: 0.296, 95% CI: 0.098–0.889). Meanwhile, a SOFA score ≥8 was independently associated with 28-day in-hospital mortality (adjusted OR: 2.842, 95% CI: 1.042–7.753).
5.      Patients in the survivor group were more likely to have a clinical response to tocilizumab by day 28 (80.4% vs 5.7%; p < 0.001). Improvements in the six-point ordinal scale and SOFA score were observed in survivors after tocilizumab. Further, the hospital length of stay was longer in the survivor group compared to non-survivors (27.5 days [14–31] vs 14 days [9–20]; p < 0.001), while 14 (17.3%) patients remained hospitalized at the end of the study.